Blues Brief



For oncology providers

Finding the latest coronavirus (COVID-19) provider information

Our provider communications about the COVID-19 pandemic can be found on the Coronavirus (COVID-19) information updates for providers webpage located within BCBSM Newsletters and Resources or BCN Provider Publications and Resources on web-DENIS. Our public webpage for providers is located at bcbsm.com/coronavirus. Click on For providers.

Recommendations for submitting authorization requests for medical oncology drugs to AIM

Follow these recommendations for submitting authorization requests for medical oncology drugs to AIM Specialty Health® to ensure a more efficient authorization review process:

- Wait to submit the request until you have all the pertinent information, including but not limited to, tumor testing results, information on tumor staging and prior therapy regimens.
- Provide **all** the clinical information needed for clinical review, including the rationale for the requested regimen.
- Be sure the phone number provided is accurate if AIM needs to contact you to schedule a peer-to peer consultation for more information to establish medical necessity.

This information applies to all Blue Cross PPO, Medicare Plus BlueSM PPO, BCN HMOSM and BCN AdvantageSM members whose plans require authorization of medical oncology drugs by AIM.

For more information, see Page 27 of the July-August 2020 BCN Provider News or the June 2020 issue of The Record.

drug prior authorization lists are changing in July and August for Medicare Plus BlueSM PPO, **BCN HMOSM and BCN AdvantageSM** members

We're adding authorization requirements for four specialty drugs covered under the medical benefit for Medicare Plus Blue PPO, BCN HMO and BCN Advantage members.

For dates of service on or after July 24, 2020, the following drugs will require authorization through AIM Specialty Health®:

- Trodelvy™ (sacituzumab govitecan-hziy, J3490, J3590, J9999)
- Jelmyto[™] (mitomycin, J3490, J3590, J9999)
- Darzalex Faspro™ (daratumumab and hyaluronidase-fihi, J3490, J3590, J9999)

For dates of service on or after Aug. 24, 2020, the following drug will require authorization through AIM:

• Imlygic® (talimogene laherparepvec, J9325)

For more information, see Page 13 of the July-August 2020 BCN Provider News or the July 2020 issue of The Record.

Two UAW groups have similar names, causing some confusion

Because of their similar names, there has been some confusion about whether the UAW Retiree Health Care Trust, UAW International Staff or UAW Retiree Medical Benefits Trust require prior authorization from AIM Specialty Health for select outpatient medical diagnostic services. Keep in mind that the URHCT and the UAW International Staff do not require preauthorization, while URMBT does. For more information, see the May 2020 issue of The Record.

Continued on the next page

Articles apply to all lines of business unless noted by the icons below:






Key: HMO BCN HMOSM







Blues Brief



For oncology providers

Continued from front page

eviCore healthcare® updates

• eviCore simplifies authorization process for radiation oncology

Beginning July 1, 2020, eviCore healthcare simplified the authorization process for radiation oncology so that you'll see fewer clinical questions on authorization requests. As part of the process, eviCore will be asking clinical decision support questions, rather than traditional clinical questions. This change applies to authorizations for breast, prostate and non-small-cell lung cancer.

For more information, see the August 2020 issue of The Record, and Blue Cross eviCore-Managed Procedures and BCN eviCore-Managed Procedures pages of ereferrals.bcbsm.com.


Policy on hypofractionation for breast and prostate cancer revised

Blue Cross Blue Shield of Michigan and Blue Care Network have revised the radiation oncology program managed through eviCore healthcare to limit coverage to hypofractionation (a shorter, equally effective regimen) for many breast and prostate cancers, effective for requests submitted on or after Sept. 21. The changes align with evidencebased guidelines including the National Comprehensive Cancer Network, or NCCN. The change will result in less frequent visits for patients.

For more information, see the upcoming issues of the September-October 2020 BCN Provider News or the September 2020 issue of The Record.

New quantity limits for morphine





A prior authorization is required for members who received a prescription on or after May 1, 2020, under the new quantity limits.

For more information, see Page 30 of the May-June 2020 BCN Provider News or the March 2020 issue of The Record.

Radiation therapy services for A9590 require prior authorization for all Blue Cross, BCN members

For dates of service on or after April 1, 2020, services associated with HCPCS code A9590 (iodine i-131, iobenguane, 1 millicurie) require prior authorization by eviCore healthcare.

This applies to all Blue Cross and BCN members with plans subject to eviCore healthcare authorization requirements. For more information, see Page 35 of the March–April 2020 BCN Provider News or the March 2020 issue of The Record.

HEDIS® measure tip sheets updated for 2020

We've updated our HEDIS tip sheets for 2020 and posted them on the Clinical Quality Corner page of web-DENIS, along with a series of Star Measure Tips that were posted earlier this year. The tip sheets were developed to assist health care providers and their staff in their efforts to improve overall health care quality and prevent or control diseases and chronic conditions.

For more details, see the May 2020 issue of The

HEDIS® is a registered trademark of the National Committee for Quality Assurance.

Articles apply to all lines of business unless noted by the icons below:









